Skip to main content
OpenTrials
Completed

NCT Number: NCT05504135

Implementation of Pre-emptive Pharmacogenomics Testing in Singapore-based Private Hospital Institutions (IMPT Study)

In collaboration with Raffles Medical Group, we will be recruiting 500 patients and following them for the next 3-12 months to see whether pharmacogenomics information provided in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pre-emptive Pharmacogenomics

Age range

21 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Raffles Hospital

Singapore, 188770

About this study

Pre-emptive genotyping provides relevant genomic data to physicians to facilitate prescribing and to facilitate checking of prescriptions by pharmacists to ensure drug safety and efficacy. This essential information should be incorporated into electronic healthcare systems and should be readily available. The effectiveness of pre-emptive genotyping to reduce adverse drug reactions (ADRs) is unknown in Singapore. Hence, this study is designed to evaluate whether it is feasible to implement large scale pre-emptive genotyping program at a hospital in Singapore and aim to integrate genomic medicine into clinical practice to improve drug safety and efficacy.

This study involves the testing of feasibility of pharmacogenomic genotyping in hospitals whereby our pharmacogenomics panel tests for 5 genes (CYP2D6, CYP2C9, CYP2C19, SLCO1B1 and HLA-B*58:01) which influences patient's response to more than 165 medications. Reports will be generated for all drugs that have been reported to be in CPIC Level A/B of association with the genes/haplotypes. The patients who are given these tests for free are recommended due to having experienced at least one of the diseases in our list or is at a risk of developing them.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who experienced at least one of the following diseases, or is at risk of developing them:
  • Diabetes Mellitus
  • Hypertension
  • Hyperlipidaemia
  • Ischaemic Heart Disease
  • Stroke
  • Osteoarthritis
  • Rheumatoid Arthritis
  • Gout
  • Anxiety
  • Major Depression

Exclusion criteria

  • Below ages 21 and above ages 65

Treatment and study plan

Pharmacogenomics Testing

Diagnostic Test

To test if pharmacogenomics information (produced from testing) included by us in the Raffles' Electronic Health Records (EHR) will be used by physicians to personalize patients' prescriptions.

Primary outcomes

  1. Turnaround time of genotype result, compared to expected

    Time frame: 6 months

  2. Overall satisfaction of patient

    Time frame: 0 months

    Via survey upon recruitment

  3. Overall satisfaction of patient

    Time frame: 3 month

    Via survey at month 3 of the study

  4. Overall satisfaction of patient

    Time frame: 12 months

    Via survey at month 12 of the study

  5. Overall satisfaction of site principal investigators

    Time frame: 6 months

    Via survey done at month 6 of the study

  6. Overall satisfaction of prescribing physicians

    Time frame: 12 months

    Via survey done at month 12 of the study

  7. Prevalence of clinically actionable genotypes

    Time frame: 12 months

    The number of patients receiving recommendations that includes a certain follow up action which includes monitoring, change of dosing or change of prescription.

  8. Recommendation acceptance rate

    Time frame: 12 months

    Defined by: (1) Number of physicians who are interested to consider pharmacogenomics information to guide prescription, measured by click-through rate of Pharmacogenomics Access Button; (2) Number of changes made to the medications post-PGx testing; (3) Data obtained from satisfaction survey for prescribing physicians

Sponsors and collaborators

Lead sponsor

Nalagenetics Pte Ltd

Industry

Registry information

Important dates

Study start
2022
Primary completion
2023
Study completion
2024
First posted
Aug 17, 2022
Registry last updated
May 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.